Protagenic Therapeutics Revenue vs. Beta
| PTIXW Stock | USD 0.01 0.00 0.00% |
Total Revenue | First Reported 1995-09-30 | Previous Quarter 0.0 | Current Value 50.3 K | Quarterly Volatility 7.6 M |
For Protagenic Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Protagenic Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Protagenic Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Protagenic Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Protagenic Therapeutics over time as well as its relative position and ranking within its peers.
Protagenic |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.90) | Return On Equity (2.06) |
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Protagenic Therapeutics Beta vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Protagenic Therapeutics's current stock value. Our valuation model uses many indicators to compare Protagenic Therapeutics value to that of its competitors to determine the firm's financial worth. Protagenic Therapeutics is currently under evaluation in revenue category among its peers. It is regarded fourth in beta category among its peers . At this time, Protagenic Therapeutics' Total Revenue is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Protagenic Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Protagenic Revenue vs. Competition
Protagenic Therapeutics is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 0.0. Protagenic Therapeutics adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.
Protagenic Beta vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Protagenic Therapeutics |
| = | null |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Protagenic Therapeutics |
| = | 0.25 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Protagenic Beta Comparison
Protagenic Therapeutics is currently under evaluation in beta category among its peers.
Beta Analysis
As returns on the market increase, Protagenic Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Protagenic Therapeutics is expected to be smaller as well.
Protagenic Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Protagenic Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Protagenic Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Protagenic Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Protagenic Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -113.5 K | -119.2 K | |
| Operating Income | -4.5 M | -4.8 M | |
| Income Before Tax | -5 M | -5.3 M | |
| Total Other Income Expense Net | -473.5 K | -497.2 K | |
| Net Loss | -5 M | -5.3 M | |
| Income Tax Expense | 2.00 | 1.90 | |
| Interest Income | 303.2 K | 172.1 K | |
| Net Loss | -2.3 M | -2.4 M | |
| Net Interest Income | 176.5 K | 185.3 K | |
| Net Loss | -3.9 M | -4.1 M | |
| Net Loss | (1.15) | (1.21) | |
| Income Quality | 0.74 | 0.95 | |
| Net Income Per E B T | 0.91 | 0.76 |
Protagenic Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Protagenic Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Protagenic Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Protagenic Therapeutics' important profitability drivers and their relationship over time.
Use Protagenic Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Protagenic Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protagenic Therapeutics will appreciate offsetting losses from the drop in the long position's value.Protagenic Therapeutics Pair Trading
Protagenic Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Protagenic Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Protagenic Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Protagenic Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Protagenic Therapeutics to buy it.
The correlation of Protagenic Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Protagenic Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Protagenic Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Protagenic Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Protagenic Therapeutics position
In addition to having Protagenic Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Toys Thematic Idea Now
Toys
Companies producing and distributing toys and different gaming products for kids. The Toys theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Toys Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.